Results 111 to 120 of about 231,599 (208)

Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. <i>Cancers</i> 2021, <i>13</i>, 6256. [PDF]

Cancers (Basel)
Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, Hernández-Pedro NY, Ortega-Gómez A, Lara-Mejía L, Rangel-Escareño C, Arrieta O.   +14 more
europepmc   +1 more source

Over the edge: Empirical evidence for the cliff‐edge model of obstetric selection

The Anatomical Record, EarlyView.
Abstract The cliff‐edge model of obstetric selection maintains that larger neonates and smaller birth canals confer a positive selective advantage until labor becomes obstructed and vaginal delivery is no longer possible, eliciting an abrupt reduction in fitness.
Laura M. Watson, Pierre Frémondière, Kaspar Staub, Philipp Mitteroecker, Barbara Fischer, Martin Haeusler, Nicole M. Webb   +6 more
wiley   +1 more source

Mapping Sanfilippo Syndrome: A Multisystem Clinicopathological Autopsy. [PDF]

Diagnostics (Basel)
Trandafirescu MF, Avădănei ER, Filip N, Saveanu CI, Foia I, Toma V, Baroi LG, Anton-Paduraru DT, Moisa SM, Lozneanu L.   +9 more
europepmc   +1 more source

Effects of Dietary Mannan Oligosaccharides on Growth, Disease Resistance, and Gut Microbiota in Zebrafish

Animal Research and One Health, EarlyView.
Supplementation with mannan oligosaccharides (MOS) enhances growth, disease resistance, antioxidant capacity, and gut microbiota diversity while suppressing inflammation, apoptosis, and strengthening intestinal barrier integrity in zebrafish challenged with LPS or DSS.
Zhiyuan Lu, Longjiang Tang, Lei Deng, Ziheng Ren, Zhiyuan Gong   +4 more
wiley   +1 more source

Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source

DNA Electrochemical Sensor Based on Exonuclease III-Assisted Cycling Signal Amplification for Ultrasensitive Detection of Genetically Modified Soybean. [PDF]

Biosensors (Basel)
Niu L, Huang S, Zhao J, Yang W, Li Z, Niu S, Yang J, Chen S, Wang Q.   +8 more
europepmc   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Cutaneous Melanoma in Adolescents and Young Adults Versus Older Patients: Clinical and Histopathological Differences in Western Romania. [PDF]

Dermatopathology (Basel)
Natarâş BR, Tăban SM, Jurescu A, Viţa OC, Cornea RF, Hurmuz I, Vidac A, Grujic D, Popa VT, Dema ALC.   +9 more
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Immune Phenotyping Using Neutrophil-to-Lymphocyte Ratio and Tumor-Infiltrating Lymphocytes Predicts Recurrence in Resected Melanoma. [PDF]

Diagnostics (Basel)
Ekin O, Aktepe OH.
europepmc   +1 more source